Interleukin-2 in cancer

Emerging Drugs

Volumn 5, Issue 3, 2000, Pages 273-285

  Gurjal, A ^a   Philip, P A ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Cancer; IL 2; Recombinant IL 2

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CARMUSTINE; CISPLATIN; CYTOKINE; CYTOTOXIC AGENT; DACARBAZINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HISTAMINE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 4; MAXAMINE; MONOCLONAL ANTIBODY CD3; PROPEUKIN; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TUMOR VACCINE; VINBLASTINE;

ANTIGEN PRESENTING CELL; BLOOD DISEASE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; GENE THERAPY; HUMAN; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG TOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NATURAL KILLER CELL; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 0033781022     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.3.273     Document Type: Review

References (88)

1. Interleukin-2: Inception, impact and implications
2. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2
3. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
4. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2
5. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
6. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation
7. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
8. Cancer statistics, 1999
9. Cutaneous melanoma
10. Prognostic factors in metastatic melanoma
11. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience
12. Systemic therapy in melanoma
13. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma: Late results
14. Current treatment options for malignant melanoma
15. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial
16. Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma
17. Interferon-2a and dacarbazine in melanoma
18. Multicenter randomized trial of dacarbazine alone or in combination of two different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma
19. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
20. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers
21. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma
22. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
23. Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study
24. Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alpha-2a in patients with advanced melanoma
25. Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection
26. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study
27. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
28. Interleukin-2 in therapy of hematologic malignancies
29. Metastatic renal cell carcinoma: Long-term survival after therapy with high-dose continuous infusion interleukin-2
30. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma
31. Randomized Phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma
32. Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997
33. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: Prolonged immunomodulation without significant toxicity
34. Effects of low-dose recombinant interleukin-2 in human malignancies
35. A Phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects
36. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
37. A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma
38. A Phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions
39. Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer
40. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: A Phase I study
41. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial
42. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
43. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer
44. A phase I study of prolonged continous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects
45. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report
46. Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
47. Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: Antitumor activity and immunomodulatory effects
48. Subcutaneous interleukin-2, interferon alpha-2a and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter Phase II trial. Groupe Francais d'Immunotherapie
49. Outpatient treatment with subcutaneous interleukin-2 and interferon alpha administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized Phase II study. Subcutaneous Administration Propeukin Program Cooperative Group
50. Effective chemotherapy for melanoma after treatment with interleukin-2
51. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha and interleukin-2 for patients with metastatic melanoma
52. Combination of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma
53. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b
54. Histamine and cytokine therapy
55. A two-part Phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor
56. A Phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients
57. A Phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients
58. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: Clinical and immunologic effects
59. Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alpha-2a (IFN alpha) in metastatic melanoma
60. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: A Phase I study
61. A Phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer and malignant melanoma
62. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor and tamoxifen for patients with metastatic melanoma
63. Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma
64. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy and in 12 advanced patients
65. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: A pilot study
66. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2
67. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines
68. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization and antitumor activity
69. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
70. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy
71. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infilterating lymphocytes in human renal cell carcinoma
72. Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, alpha interferon and tumor-infiltrating lymphocytes
73. Immunotherapy with low-dose interleukin-2: Rationale for prevention of immune-deficiency-associated cancer
74. Human melanoma cells express a functional interleukin-2 receptor
75. The release of interleukin-8 during intravenous bolus treatment with interleukin-2
76. In vivo cytokine production and recombinant interleukin 2 immunotherapy: An insight into the possible mechanisms underlying clinical responses
77. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients
78. Rapid cytokine release in cancer patients treated with interleukin-2
79. Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2)
80. Circulating intercellular adhesion molecule-1 in melanoma patients: Induction by interleukin-2 therapy
81. Nitric oxide synthase activity in human renal cell carcinoma
82. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy
83. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
84. Potential for protein kinase C inhibitors in cancer therapy
85. Rational interleukin-2 therapy
86. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
87. High-dose aldesleukin in renal cell carcinoma: Long term survival update
88. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer